Targeting the Fanconi Anemia Pathway to Identify Tailored Anticancer Therapeutics

<table>EF24 is selectively toxic to ATM-deficient cells [<a href="../#B70">57</a>]. 309ATM-deficient and 334ATM wild type cells were treated with the FA pathway inhibitor EF24. Cell viability was measured after 3 days by MTS assay. Each point represents the mean of 3 repeats. Error bars represent standard deviation.</table>

Anemia

fig3

Figure 3

Figure 3: Targeting the Fanconi Anemia Pathway to Identify Tailored Anticancer Therapeutics 